Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Colorectal Cancer Reports
Published in: Current Colorectal Cancer Reports 4/2013

01-12-2013 | Immunotherapy of Malignancy (MA Morse, Section Editor)

Modulation of Immune System Inhibitory Checkpoints in Colorectal Cancer

Authors: Sandip P. Patel, Takuya Osada, Koya Osada, Herbert Hurwitz, H. Kim Lyerly, Michael A. Morse

Published in: Current Colorectal Cancer Reports | Issue 4/2013

Login to get access

Abstract

T cell infiltration of colorectal cancer is associated with improved clinical outcome, underlining the importance of the immune system in cancer control; however, immune checkpoints, including the inhibitory T cell molecules CTLA-4 and PD-1 that temper the native immune response, mitigating autoimmunity, are coopted by tumors to facilitate escape from immune surveillance. Blockade of CTLA-4 and PD-1 and its ligand PD-L1, expressed by many tumors, have shown impressive activity in melanoma, renal cell carcinoma, and lung cancer. Immune checkpoint inhibition has been less well studied in colorectal cancer, but preclinical and clinical investigations are in progress.
Literature
1.
2.
Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335–42.PubMedCrossRef
3.
Sandler A, Gray R, Ph D, et al.. Paclitaxel–carboplatin alone or with bevacizumab for non–small-cell lung cancer. 2006; 2542-2550
4.
Chu E. An update on the current and emerging targeted agents in metastatic colorectal cancer. Clin Colorectal Cancer. 2012;11:1–13.PubMedCrossRef
5.
Pagès F, Galon J, Dieu-Nosjean M-C, et al. Immune infiltration in human tumors: a prognostic factor that should not be ignored. Oncogene. 2010;29:1093–102.PubMedCrossRef
6.
Osada T, Hsu D, Hammond S, et al. Metastatic colorectal cancer cells from patients previously treated with chemotherapy are sensitive to T cell killing mediated by CEA/CD3-bispecific T cell-engaging BiTE antibody. Br J Cancer. 2009;102:124–33.PubMedCrossRef
7.
Ferrone C, Dranoff G. Dual roles for immunity in gastrointestinal cancers. J Clin Oncol. 2010;28:4045–51.PubMedCrossRef
8.
Ellebaek E, Andersen MH, Svane IM, et al. Immunotherapy for metastatic colorectal cancer: Present status and new options. Scand j gastroenterol. 2012;47:315–24.PubMedCrossRef
9.
Boghossian S, Robinson S, Von Delwig A, et al. Immunotherapy for treating metastatic colorectal cancer. Surg Oncol. 2012;21:67–77.PubMedCrossRef
10.
Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711–23.PubMedCrossRef
11.
Hamid O, Robert C, Daud A, et al. Safety and tumor responses with lambrolizumab (Anti–PD-1) in Melanoma. N Engl J Med 0:null
12.
Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 0:null
13.
•• Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366:2443–54. Large phase 1 trial assessing anti-PD-1 and establishment of PD-L1 on tumor as putative predictive biomarker for response.PubMedCrossRef
14.
•• Brahmer JR, Tykodi SS, Chow LQM, et al. Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer. N Engl J Med. 2012;366:2455–65. Large phase 1 trial assessing anti-PD-L1 therapy.PubMedCrossRef
15.
Prieto PA, Yang JC, Sherry RM, et al. CTLA-4 Blockade with Ipilimumab: Long-term Follow-up of 177 Patients with Metastatic Melanoma. Clin Cancer Res. 2012;18:2039–47.PubMedCrossRef
16.
Bretscher PA. A two-step, two-signal model for the primary activation of precursor helper T cells. Proc Natl Acad Sci. 1999;96:185–90.PubMedCrossRef
17.
• Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12:252–64. Excellent review of basic biology of immune checkpoints and translational development of immune checkpoint inhibitors.PubMedCrossRef
18.
Peggs KS, Quezada SA, Chambers CA, et al. Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodies. J exp med. 2009;206:1717–25.PubMedCrossRef
19.
Waterhouse P, Penninger JM, Timms E, et al. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science. 1995;270:985–8.PubMedCrossRef
20.
Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science. 1996;271:1734–6.PubMedCrossRef
21.
Keir ME, Liang SC, Guleria I, et al. Tissue expression of PD-L1 mediates peripheral T cell tolerance. J exp med. 2006;203:883–95.PubMedCrossRef
22.
Francisco LM, Salinas VH, Brown KE, et al.: PD-L1 regulates the development , maintenance , and function of induced regulatory T cells. 206:3015–3029, 2009
23.
Curran MA, Montalvo W, Yagita H, et al. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci. 2010;107:4275–80.PubMedCrossRef
24.
Sharpe AH, Wherry EJ, Ahmed R, et al. The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat Immunol. 2007;8:239–45.PubMedCrossRef
25.
Barber DL, Wherry EJ, Masopust D, et al. Restoring function in exhausted CD8 T cells during chronic viral infection. nature. 2005;439:682–7.PubMedCrossRef
26.
Zou W, Chen L. Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol. 2008;8:467–77.PubMedCrossRef
27.
Blank C, Gajewski T, Mackensen A. Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy. Cancer Immunol Immunother. 2005;54:307–14.PubMedCrossRef
28.
Blank C, Mackensen A. Contribution of the PD-L1/PD-1 pathway to T cell exhaustion: an update on implications for chronic infections and tumor evasion. Cancer Immunol Immunother. 2007;56:739–45.PubMedCrossRef
29.
Iwai Y, Ishida M, Tanaka Y, et al. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci. 2002;99:12293–7.PubMedCrossRef
30.
Hamanishi J, Mandai M, Iwasaki M, et al. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci. 2007;104:3360–5.PubMedCrossRef
31.
Hino R, Kabashima K, Kato Y, et al. Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma. Cancer. 2010;116:1757–66.PubMedCrossRef
32.
Mu C-Y, Huang J-A, Chen Y, et al. High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation. Med Oncol. 2011;28:682–8.PubMedCrossRef
33.
Thompson RH, Kuntz SM, Leibovich BC, et al. Tumor B7-H1 Is Associated with Poor Prognosis in Renal Cell Carcinoma Patients with Long-term Follow-up. Cancer Res. 2006;66:3381–5.PubMedCrossRef
34.
Smyrk TC, Watson P, Kaul K, et al. Tumor-infiltrating lymphocytes are a marker for microsatellite instability in colorectal carcinoma. Cancer. 2001;91:2417–22.PubMedCrossRef
35.
Ogino S, Nosho K, Irahara N, et al. Lymphocytic Reaction to Colorectal Cancer Is Associated with Longer Survival, Independent of Lymph Node Count, Microsatellite Instability, and CpG Island Methylator Phenotype. Clin Cancer Res. 2009;15:6412–20.PubMedCrossRef
36.
Pagès F, Berger A, Camus M, et al. Effector Memory T Cells, Early Metastasis, and Survival in Colorectal Cancer. N Engl J Med. 2005;353:2654–66.PubMedCrossRef
37.
• Pagès F, Kirilovsky A, Mlecnik B, et al. In Situ Cytotoxic and Memory T Cells Predict Outcome in Patients With Early-Stage Colorectal Cancer. J Clin Oncol. 2009;27:5944–51. Development of prognostic immunoscore assessing effector and memory T cells within colorectal tumor specimens which are associated with improved prognosis.PubMedCrossRef
38.
Naito Y, Saito K, Shiiba K, et al. CD8+ T Cells Infiltrated within Cancer Cell Nests as a Prognostic Factor in Human Colorectal Cancer. Cancer Res. 1998;58:3491–4.PubMed
39.
Salama P, Phillips M, Grieu F, et al. Tumor-Infiltrating FOXP3+ T Regulatory Cells Show Strong Prognostic Significance in Colorectal Cancer. J Clin Oncol. 2009;27:186–92.PubMedCrossRef
40.
Dewan MZ, Galloway AE, Kawashima N, et al. Fractionated but Not Single-Dose Radiotherapy Induces an Immune-Mediated Abscopal Effect when Combined with Anti–CTLA-4 Antibody. Clin Cancer Res. 2009;15:5379–88.PubMedCrossRef
41.
Kocak E, Lute K, Chang X, et al. Combination Therapy with Anti–CTL Antigen-4 and Anti-4-1BB Antibodies Enhances Cancer Immunity and Reduces Autoimmunity. Cancer Res. 2006;66:7276–84.PubMedCrossRef
42.
Hirano F, Kaneko K, Tamura H, et al. Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer res. 2005;65:1089–96.PubMed
43.
Dong H, Strome SE, Salomao DR, et al. Tumor-associated B7-H1 promotes T cell apoptosis: a potential mechanism of immune evasion. Nat med. 2002;8:793–800.PubMedCrossRef
44.
M. Grimm MG, M. Koenigshausen, C. Stein, J. Lutz, S. Krol, A. Thiede, U. Heemann and A. Waaga-Gasser: Abstract: Clinical significance and therapeutic potential of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human colorectal cancer. J Clin Oncol 26;:suppl 15005 (ASCO Meeting Abstracts), 2008
45.
Terme M, Ullrich E, Aymeric L, et al. IL-18 Induces PD-1–Dependent Immunosuppression in Cancer. Cancer Res. 2011;71:5393–9.PubMedCrossRef
46.
Iwai Y, Terawaki S, Honjo T. PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells. Int immunol. 2005;17:133–44.PubMedCrossRef
47.
Yu P, Steel JC, Zhang M, et al. Simultaneous Blockade of Multiple Immune System Inhibitory Checkpoints Enhances Antitumor Activity Mediated by Interleukin-15 in a Murine Metastatic Colon Carcinoma Model. Clin Cancer Res. 2010;16:6019–28.PubMedCrossRef
48.
Ngiow SF, von Scheidt B, Akiba H, et al. Anti-TIM3 Antibody Promotes T Cell IFN-γ–Mediated Antitumor Immunity and Suppresses Established Tumors. Cancer res. 2011;71:3540–51.PubMedCrossRef
49.
Sakuishi K, Apetoh L, Sullivan JM, et al. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med. 2010;207:2187–94.PubMedCrossRef
50.
Tel J, Hato SV, Torensma R, et al. The chemotherapeutic drug oxaliplatin differentially affects blood DC function dependent on environmental cues. Cancer Immunol Immunother. 2012;61:1101–11.PubMedCrossRef
51.
Lesterhuis WJ, Punt CJ, Hato SV, et al. Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice. J clin investig. 2011;121:3100.PubMedCrossRef
52.
Pander J, Heusinkveld M, van der Straaten T, et al. Activation of Tumor-Promoting Type 2 Macrophages by EGFR-Targeting Antibody Cetuximab. Clin Cancer Res. 2011;17:5668–73.PubMedCrossRef
53.
Pander J, Gelderblom H, Antonini NF, et al. Correlation of FCGR3A and EGFR germline polymorphisms with the efficacy of cetuximab in KRAS wild-type metastatic colorectal cancer. Eur j cancer (Oxford, England : 1990). 2010;46:1829–34.CrossRef
54.
Simon Pernot MT, Marcheteau E, Voron T, Colussi O, Tartour E, Taïeb J. Impact of antiangiogenic treatments on exhausted PD-1+ T lymphocytes in colorectal cancer. J Clin Oncol, 2013
55.
Petty JK, He K, Corless CL, et al. Survival in human colorectal cancer correlates with expression of the T cell costimulatory molecule OX-40 (CD134). Am J Surg. 2002;183:512–8.PubMedCrossRef
56.
Pan PY, Zang Y, Weber K, et al. OX40 ligation enhances primary and memory cytotoxic T lymphocyte responses in an immunotherapy for hepatic colon metastases. Mol Ther. 2002;6:528–36.PubMedCrossRef
57.
Martinet O, Ermekova V, Qiao JQ, et al. Immunomodulatory Gene Therapy With Interleukin 12 and 4-1BB Ligand: Long- Term Remission of Liver Metastases in a Mouse Model. J Natl Cancer Inst. 2000;92:931–6.PubMedCrossRef
58.
59.
Lynch T, Bondarenko I, Luft A, et al. Phase II trial of ipilimumab (IPI) and paclitaxel/carboplatin (P/C) in first-line stage IIIb/IV non-small cell lung cancer (NSCLC). J Clin Oncol. 2010;28:7531.CrossRef
60.
NCT01769222: Ipilimumab and Local Radiation Therapy in Treating Patients With Recurrent Melanoma, Non-Hodgkin Lymphoma, Colon, or Rectal Cancer (Phase 1/2).
61.
Chung KY, Gore I, Fong L, et al. Phase II Study of the Anti-Cytotoxic T-Lymphocyte–Associated Antigen 4 Monoclonal Antibody, Tremelimumab, in Patients With Refractory Metastatic Colorectal Cancer. J Clin Oncol. 2010;28:3485–90.PubMedCrossRef
62.
•• Wolchok JD, Hoos A, O'Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15:7412–20. Excellent overview of the novel immune response criteria and definitions of progression related to all immunotherapeutics.PubMedCrossRef
63.
•• Hoos A, Eggermont AMM, Janetzki S, et al. Improved endpoints for cancer immunotherapy trials. J Natl Cancer Inst. 2010;102:1388–97. Comprehensive overview of the pitfalls of classical clinial trial design and statistical criteria in evaluating immunotherapy.PubMedCrossRef
64.
Ribas A, Kefford R, Marshall MA, et al. Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced Melanoma. J Clin Oncol. 2013;31:616–22.PubMedCrossRef
65.
Brahmer JR, Drake CG, Wollner I, et al. Phase I study of single-agent anti–programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol. 2010;28:3167–75.PubMedCrossRef
Metadata
Title
Modulation of Immune System Inhibitory Checkpoints in Colorectal Cancer
Authors
Sandip P. Patel
Takuya Osada
Koya Osada
Herbert Hurwitz
H. Kim Lyerly
Michael A. Morse
Publication date
01-12-2013
Publisher
Springer US
Published in
Current Colorectal Cancer Reports / Issue 4/2013
Print ISSN: 1556-3790
Electronic ISSN: 1556-3804
DOI
https://doi.org/10.1007/s11888-013-0184-3

Other articles of this Issue 4/2013

Current Colorectal Cancer Reports 4/2013 Go to the issue

Translational Colorectal Oncology (Y Jiang, Section Editor)

Oncotype DX for Colon Cancer: Are We Ready for Prime Time in Personalized Medicine?

Immunotherapy of Malignancy (MA Morse, Section Editor)

Status of Active Specific Immunotherapy for Stage II, Stage III, and Resected Stage IV Colon Cancer

Molecular Biology (S Anant, Section Editor)

Molecular Origins of Colon and Rectal Cancer: Not a Wnt–Wnt Situation

Translational Colorectal Oncology (Y Jiang, Section Editor)

How Do We Make Choices in Salvage Therapy: Panitumumab, Cetuximab, or Regorafenib?

Molecular Biology (S Anant, Section Editor)

Stem Cell Signaling Pathways in Colorectal Cancer

Molecular Biology (S Anant, Section Editor)

Reactive Oxygen Species and Colorectal Cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits